Side-by-side · Research reference
ARA 290vsFOXO4-DRI
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BAnimal-StrongHUMAN-REVIEWED12/45 cited
FOXO4-DRI
Senolytic Peptide · D-Retro-Inverso
SQ · Animal models only
01Mechanism of Action
Parameter
ARA 290
FOXO4-DRI
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
FOXO4-p53 protein complex in senescent cellsBourgeois 2025Tripathi 2021
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021Alameen 2026
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
FOXO4-DRI
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
Weeks to months (animal studies)
Senescent cell clearance observed within weeks.
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Animal / mechanistic
Timing
Any time of day
No circadian dependence reported.
—
Animal dose (mouse)
—
5 mg/kg
SQ injection, aged mouse model (testosterone restoration).
Frequency (animal)
—
Variable — single or intermittent dosing
Protocol-dependent; no standardised regimen.
Human equivalent (theoretical)
—
~0.4 mg/kg (28 mg / 70 kg adult)
Extrapolated using allometric scaling; no clinical validation.
Clinical status
—
No human trials completed
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
FOXO4-DRI
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
FOXO4-DRI
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Pulmonary hypertension risk
—
Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023
Context-dependent toxicity
—
Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023
Off-target apoptosis
—
Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)
Immune perturbation
—
Senescent cells contribute to immune surveillance; clearance effects unknown
Human safety unknown
—
No clinical trials — toxicity profile in humans not established
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
FOXO4-DRI
- ·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
FOXO4-DRI
- ·Active malignancy (senescence as tumour suppressor mechanism)
- ·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)
05Administration Protocol
Parameter
ARA 290
FOXO4-DRI
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Subcutaneous injection used in rodent models. No human administration protocol exists.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
FOXO4-DRI
— no documented stacks